2025
American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary
Siegal D, Tseng E, Schünemann H, Angchaisuksiri P, Cuker A, Dane K, DeSancho M, Diuguid D, Griffin D, Klok F, Lee A, Neumann I, Pai A, Righini M, Sanfilippo K, Terrell D, Akl E, Al Jabiri R, Al Jabiri Y, Barbara A, Bognanni A, Akl I, Boulos M, Brignardello-Petersen R, Chan M, Charide R, Colunga-Lozano L, Dearness K, Darzi A, Hussein H, Karam S, Kolb P, Mansour R, Morgano G, Morsi R, Muti-Schünemann G, Nadim M, Noori A, Philip B, Piggott T, Qiu Y, Benitez Y, Schünemann F, Stevens A, Solo K, Wiercioch W, Mustafa R, Nieuwlaat R. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Advances 2025, 9: 1247-1260. PMID: 39437797, PMCID: PMC11950770, DOI: 10.1182/bloodadvances.2024014219.Peer-Reviewed Original ResearchConceptsCOVID-19-related critical illnessConditional recommendationAcute illnessHealth care professionalsAmerican Society of HematologyProphylactic-intensity anticoagulationCritical illnessEvidence-based recommendationsVenous thromboembolismRandomized Controlled TrialsCare professionalsPatient representativesRisk of venous thromboembolismGuideline developmentRecommendations AssessmentTherapeutic-intensity anticoagulationExecutive summaryLiving guidelinesMultidisciplinary panelIncreased risk of venous thromboembolismSystematic reviewAssessed certaintyCOVID-19-relatedControlled TrialsMcMaster University
2024
Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network
DeSancho M, Suvar E, Roberts J, Tarantino M, Schwartz J, Callis J, Recht M. Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network. Journal Of Thrombosis And Haemostasis 2024, 22: 3183-3190. PMID: 39151704, DOI: 10.1016/j.jtha.2024.07.026.Peer-Reviewed Original ResearchConceptsHereditary antithrombin deficiencyLow-molecular-weight heparinVenous thromboembolismOral anticoagulantsAT concentrateAdverse eventsIncreased risk of venous thromboembolismRisk factorsRisk of venous thromboembolismDirect oral anticoagulantsAmerican ThrombosisSeventy-nine patientsDeep vein thrombosisHemostasis NetworkRecurrent thrombosisConcentrate administrationPulmonary embolismAntithrombin deficiencyThrombotic eventsVein thrombosisProspective studyPredominant manifestationArterial thrombosisGlobal RegistryIncreased risk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply